Top

Osteoporosis International

Published in:

01-05-2017 | Original Article

Use of proton pump inhibitors and mortality after hip fracture in a nationwide study

Authors: W. Brozek, B. Reichardt, J. Zwerina, H. P. Dimai, K. Klaushofer, E. Zwettler

Published in: Osteoporosis International | Issue 5/2017

Abstract

Summary

We analyzed the association of proton pump inhibitors (PPIs) with mortality after osteoporosis-related hip fracture in Austria. PPIs were associated with reduced 90-day mortality but elevated mortality after half a year when initiated pre-fracture. Inpatients and discharged patients on PPIs showed lowered in-hospital and 90-day mortality, respectively.

Introduction

We herein investigated use of proton pump inhibitors (PPIs) and mortality among hip fracture patients in a nationwide study in Austria.

Methods

In this retrospective cohort study, data on use of PPIs were obtained from 31,668 Austrian patients ≥50 years with a hip fracture between July 2008 and December 2010. All-cause mortality in patients without anti-osteoporotic drug treatment who had received their first recorded PPI prescription in the study period either before or after fracture was compared with hip fracture patients on neither PPIs nor anti-osteoporotic medication using logistic and Cox regression analysis.

Results

With PPI use, 90-day mortality was significantly reduced, both at initiation before (OR 0.66; p < 0.0001) and after hip fracture (OR 0.23; p < 0.0001). 90-day mortality was also reduced when PPIs were prescribed not until after discharge from the last recorded hip fracture-related hospital stay (OR 0.49; p < 0.0001) except for patients aged <70 years. In a sub-cohort of patients beginning PPIs during hospital stay, in-hospital mortality (0.2%) was substantially reduced relative to matched control patients (3.5%) (p < 0.0001). Longer-term mortality significantly increased after half a year post-fracture only among those who started PPI prescription before fracture.

Conclusions

PPI use during and after hospital stay due to hip fracture is associated with a considerable decrease in mortality. These findings could have implications for hip fracture treatment.

Available only for authorised users

Sambrook P, Cooper C (2006) Osteoporosis. Lancet 367:2010–2018. doi:10.1016/S0140-6736(06)68891-0 CrossRefPubMed

Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jönsson B, Kanis JA (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:136. doi:10.1007/s11657-013-0136-1 CrossRefPubMedPubMedCentral

Haentjens P, Magaziner J, Colón-Emeric CS, Vanderschueren D, Milisen K, Velkeniers B, Boonen S (2010) Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med 152:380–390. doi:10.7326/0003-4819-152-6-201003160-00008 CrossRefPubMedPubMedCentral

Heidelbaugh JJ, Goldberg KL, Inadomi JM (2010) Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting. Am J Manag Care 16:e228–e234PubMed

Desilets AR, Asal NJ, Dunican KC (2012) Considerations for the use of proton-pump inhibitors in older adults. Consult Pharm 27:114–120. doi:10.4140/TCP.n.2012.114 CrossRefPubMed

Maggio M, Lauretani F, Ceda GP, De Vita F, Bondi G, Corsonello A, Cattabiani C, Lattanzio F, Ruggiero C, Nouvenne A, Meschi T, Bandinelli S, Ferrucci L (2013) Use of proton pump inhibitors is associated with lower trabecular bone density in older individuals. Bone 57:437–442. doi:10.1016/j.bone.2013.09.014 CrossRefPubMed

Yu EW, Blackwell T, Ensrud KE, Hillier TA, Lane NE, Orwoll E, Bauer DC (2008) Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int 83:251–259. doi:10.1007/s00223-008-9170-1 CrossRefPubMedPubMedCentral

Amoako AO, Jafilan L, Nasiri P, Pujalte GG (2016) Correlation of bone mineral density scores and proton pump inhibitors use in the elderly. Curr Rheumatol Rev 12:162–166. doi:10.2174/1573397111666151026222921 CrossRefPubMed

Kwok CS, Yeong JK-Y, Loke YK (2011) Meta-analysis: risk of fractures with acid-suppressing medication. Bone 48:768–776. doi:10.1016/j.bone.2010.12.015 CrossRefPubMed

10.

Ngamruengphong S, Leontiadis GI, Radhi S, Dentino A, Nugent K (2011) Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol 106:1209–1218. doi:10.1038/ajg.2011.113 CrossRefPubMed

11.

Ye X, Liu H, Wu C, Qin Y, Zang J, Gao Q, Zhang X, He J (2011) Proton pump inhibitors therapy and risk of hip fracture: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 23:794–800. doi:10.1097/MEG.0b013e328348a56a CrossRefPubMed

12.

Yu WE, Bauer SR, Bain PA, Bauer DC (2011) Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. Am J Med 124:519–526. doi:10.1016/j.amjmed.2011.01.007 CrossRefPubMedPubMedCentral

13.

Zhou B, Huang Y, Li H, Sun W, Liu J (2016) Proton-pump inhibitors and risk of fractures: an update meta-analysis. Osteoporos Int 27:339–347. doi:10.1007/s00198-015-3365-x CrossRefPubMed

14.

Bodmer M, Meier C, Kraenzlin ME, Meier CR (2010) Proton pump inhibitors and fracture risk: true effect or residual confounding? Drug Saf 33:843–852. doi:10.2165/11536780-000000000-00000 CrossRefPubMed

15.

Vakil N (2012) Prescribing proton pump inhibitors: is it time to pause and rethink? Drugs 72:437–445. doi:10.2165/11599320-000000000-00000 CrossRefPubMed

16.

O’Connell MB, Madden DM, Murray AM, Heaney RP, Kerzner LJ (2005) Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 118:778–781. doi:10.1016/j.amjmed.2005.02.007 CrossRefPubMed

17.

Mizunashi K, Furukawa Y, Katano K, Abe K (1993) Effect of omeprazole, an inhibitor of H+, K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int 53:21–25CrossRefPubMed

18.

Pouwels S, Lalmohamed A, Souverein P, Cooper C, Veldt BJ, Leufkens HG, de Boer A, van Staa T, de Vries F (2011) Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study. Osteoporos Int 22:903–910. doi:10.1007/s00198-010-1337-8 CrossRefPubMed

19.

Yang Y-X, Lewis JD, Epstein S, Metz DC (2006) Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296:2947–2953. doi:10.1001/jama.296.24.2947 CrossRefPubMed

20.

Fisher L, Fisher A, Pavli P, Davis M (2007) Perioperative acute upper gastrointestinal haemorrhage in older patients with hip fracture: incidence, risk factors and prevention. Aliment Pharmacol Ther 25:297–308. doi:10.1111/j.1365-2036.2006.03187.x CrossRefPubMed

21.

Singh R, Trickett R, Meyer LC, Lewthwaite S, Ford D (2016) Prophylactic proton pump inhibitors in femoral neck fracture patients—a life - and cost-saving intervention. Ann R Coll Surg Engl 98:371–375. doi:10.1308/rcsann.2016.0106 CrossRefPubMedPubMedCentral

22.

Franceschi M, Di Mario F, Leandro G, Maggi S, Pilotto A (2009) Acid-related disorders in the elderly. Best Pract Res Clin Gastroenterol 23:839–848. doi:10.1016/j.bpg.2009.10.004 CrossRefPubMed

23.

Colón-Emeric CS, Mesenbrink P, Lyles KW, Pieper CF, Boonen S, Delmas P, Eriksen EF, Magaziner J (2010) Potential mediators of the mortality reduction with zoledronic acid after hip fracture. J Bone Miner Res 25:91–97. doi:10.1359/jbmr.090704 CrossRefPubMed

24.

Brozek W, Reichardt B, Zwerina J, Dimai HP, Klaushofer K, Zwettler E (2016) Anti-resorptive therapy and risk of mortality and re-fracture in osteoporosis-related hip fracture: a nationwide study. Osteoporos Int 27:387–396. doi:10.1007/s00198-015-3415-4 CrossRefPubMed

25.

Brozek W, Reichardt B, Kimberger O, Zwerina J, Dimai HP, Kritsch D, Klaushofer K, Zwettler E (2014) Mortality after hip fracture in Austria 2008–2011. Calcif Tissue Int 95:257–266. doi:10.1007/s00223-014-9889-9 CrossRefPubMed

26.

Bondo L, Eiken P, Abrahamsen B (2013) Analysis of the association between bisphosphonate treatment survival in Danish hip fracture patients—a nationwide register-based open cohort study. Osteoporos Int 24:245–252. doi:10.1007/s00198-012-2024-8 CrossRefPubMed

27.

Abrahamsen B, Eiken P, Eastell R (2011) Proton pump inhibitor use and the antifracture efficacy of alendronate. Arch Intern Med 171:998–1004. doi:10.1001/archinternmed.2011.20 PubMed

28.

Lee J, Youn KE, Choi N-K, Lee J-H, Kang DY, Song H-J, Park B-J (2013) A population-based case-control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate. J Gastroenterol 48:1016–1022. doi:10.1007/s00535-012-0722-9 CrossRefPubMed

29.

Pilotto A, Franceschi M, Vitale D, Zaninelli A, Masotti G, Rengo F (2006) Drug use by the elderly in general practice: effects on upper gastrointestinal symptoms. Eur J Clin Pharmacol 62:65–73. doi:10.1007/s00228-005-0027-5 CrossRefPubMed

30.

Kanis JA, Borgstrom F, De Laet C, Johansson H, Johnell O, Jonsson B, Oden A, Zethraeus N, Pfleger B, Khaltaev N (2005) Assessment of fracture risk. Osteoporos Int 16:581–589. doi:10.1007/s00198-004-1780-5 CrossRefPubMed

31.

Reyes C, Estrada P, Nogués X, Orozco P, Cooper C, Díez-Pérez A, Formiga F, González-Macías J, Prieto-Alhambra D (2014) The impact of common co-morbidities (as measured by the Charlson index) on hip fracture risk in elderly men: a population-based cohort study. Osteoporos Int 25:1751–1758. doi:10.1007/s00198-014-2682-9 CrossRefPubMed

32.

Moore RA, Derry S, Simon LS, Emery P (2014) Nonsteroidal anti-inflammatory drugs, gastroprotection, and benefit-risk. Pain Pract 14:378–395. doi:10.1111/papr.12100 CrossRefPubMed

33.

Santalucia P, Franchi C, Djade CD, Tettamanti M, Pasina L, Corrao S, Salerno F, Marengoni A, Marcucci M, Nobili A, Mannucci PM (2015) Gender difference in drug use in hospitalized elderly patients. Eur J Intern Med 26:483–490. doi:10.1016/j.ejim.2015.07.006 CrossRefPubMed

34.

Chow LWC, Gertsch P, Poon RTP, Branicki FJ (1998) Risk factors for rebleeding and death from peptic ulcer in the very elderly. Br J Surg 85:121–124. doi:10.1046/j.1365-2168.1998.00665.x CrossRefPubMed

35.

Bini EJ, Cohen J (2003) Endoscopic treatment compared with medical therapy for the prevention of recurrent ulcer hemorrhage in patients with adherent clots. Gastrointest Endosc 58:707–714. doi:10.1016/S0016-5107(03)02014-5 CrossRefPubMed

36.

Lau JY, Sung J, Hill C, Henderson C, Howden CW, Metz DC (2011) Systematic review of the epidemiology of complicated peptic ulcer disease: incidence, recurrence, risk factors and mortality. Digestion 84:102–113. doi:10.1159/000323958 CrossRefPubMed

37.

Masclee GMC, Sturkenboom MCJM, Kuipers EJ (2014) A benefit-risk assessment of the use of proton pump inhibitors in the elderly. Drugs Aging 31:263–282. doi:10.1007/s40266-014-0166-4 CrossRefPubMed

38.

Corleto VD, Festa S, Di Giulio E, Annibale B (2014) Proton pump inhibitor therapy and potential long-term harm. Curr Opin Endocrinol Diabetes Obes 21:3–8. doi:10.1097/MED.0000000000000031 CrossRefPubMed

39.

Wilhelm SM, Rjater RG, Kale-Pradhan PB (2013) Perils and pitfalls of long-term effects of proton pump inhibitors. Expert Rev Clin Pharmacol 6:443–451. doi:10.1586/17512433.2013.811206 CrossRefPubMed

40.

Herzig SJ, Howell MD, Ngo LH, Marcantonio ER (2009) Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA 301:2120–2128. doi:10.1001/jama.2009.722 CrossRefPubMed

41.

Howell MD, Novack V, Grgurich P, Soulliard D, Novack L, Pencina M, Talmor D (2010) Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 170:784–790. doi:10.1001/archinternmed.2010.89 CrossRefPubMed

42.

Pappas M, Jolly S, Vijan S (2016) Defining appropriate use of proton-pump inhibitors among medical inpatients. J Gen Intern Med 31:364–371. doi:10.1007/s11606-015-3536-7 CrossRefPubMed

43.

Savarino V, Dulbecco P, de Bortoli N, Ottonello A, Savarino E (2016) The appropriate use of proton pump inhibitors (PPIs): need for a reappraisal. Eur J Intern Med. doi:10.1016/j.ejim.2016.10.007 PubMed

44.

Thaler HW, Dovjak P, Iglseder B, Pinter G, Müller E, Müller W, Pils K, Mikosch P, Gerstorfer I, Zmaritz M, Weissenberger-Leduc M, Gosch M (2013) Stress ulcer prophylaxis, thromboprophylaxis and coagulation management in patients with hip fractures. Wien Med Wochenschr 163:442–447. doi:10.1007/s10354-013-0234-0 CrossRefPubMed

45.

Yood MU, Campbell UB, Rothman KJ, Jick SS, Lang J, Wells KE, Jick H, Johnson CC (2007) Using prescription claims data for drugs available over-the-counter (OTC). Pharmacoepidemiol Drug Saf 16:961–968. doi:10.1002/pds.1454 CrossRefPubMed

46.

Lam JR, Schneider JL, Zhao W, Corley DA (2013) Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA 310(22):2435–2442. doi:10.1001/jama.2013.280490 CrossRefPubMed

Title: Use of proton pump inhibitors and mortality after hip fracture in a nationwide study
Authors: W. Brozek
B. Reichardt
J. Zwerina
H. P. Dimai
K. Klaushofer
E. Zwettler
Publication date: 01-05-2017
Publisher: Springer London
Published in: Osteoporosis International / Issue 5/2017
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-017-3910-x

At a glance: The STEP trials

Springer Medicine

Use of proton pump inhibitors and mortality after hip fracture in a nationwide study

Abstract

Summary

Introduction

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2017

Cost-effectiveness of denosumab versus oral alendronate for elderly osteoporotic women in Japan

Worldwide prevalence and incidence of osteoporotic vertebral fractures

Erratum to: Use of antipsychotics increases the risk of fracture: a systematic review and meta-analysis

Standardizing 25-hydroxyvitamin D data from the HunMen cohort

Increased risk of incident osteoporosis and osteoporotic fracture in tuberculosis patients: a population-based study in a tuberculosis-endemic area

Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures